SecBot SecBot

SANA

Sana Biotechnology, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001770121 Biotech & Drug Discovery
$1.88 −0.14 (−6.93%)
Nov 16 4:00 PM ET · prev $2.02
Market cap
$602.3M
Small cap
Consensus
Buy
87% Buy or better · 15 analysts
Median target
🔒 Subscribers only
1 year
−48.4%
from $3.64 · Nov 17
30 days
−18.3%
from $2.30
52-week range
$1.88–5.18
at the low
Avg volume 20D
2.75M
shares / day
Short interest
40.60M
≈13.6% of shares · −0.6%
Days to cover
15.8
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q3 2026: 17 added (0 new), 15 trimmed or exited.

  • AnalystsBULLISH

    13 of 15 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −0.6% to 40.60M shares. 15.8 days to cover, ≈13.6% of shares.

  • TrendDOWNTREND

    30% below its 50-day average. New closing low $1.88 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYDOUBLED3,022,371$8.8M
Quadrature Capital LtdDOUBLED303,761$885.5K
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED246,670$719.0K
Squarepoint Ops LLCDOUBLED236,005$688.0K
VANGUARD ASSET MANAGEMENT, LtdADD140,692$410.1K
CITIGROUP INCTRIM128,012$373.2K
BARCLAYS PLCDOUBLED120,647$351.7K
Creative PlanningADD79,232$231.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 87% rate it Buy or better
Strong Buy6Buy7Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Aug 14, 2026B of A Securities
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 5, 2026
Bishop Hans Edgar
Director
Oct 5, 2026
AWARD8,680 sh
Aug 27, 2026
PATEL DHAVALKUMAR DHIRAJLAL
EVP, Chief Scientific Officer
Aug 27, 2026
TAX W/H$169.2K
Aug 26, 2026
PATEL DHAVALKUMAR DHIRAJLAL
EVP, Chief Scientific Officer
Aug 26, 2026
EXERCISE125,000 sh
Jul 6, 2026
Bishop Hans Edgar
Director
Jul 6, 2026
AWARD6,297 sh
Jun 4, 2026
NELSEN ROBERT
Director
Jun 4, 2026
AWARD90,000 sh
Jun 4, 2026
Bishop Hans Edgar
Director
Jun 4, 2026
AWARD90,000 sh
Jun 4, 2026
Bilenker Joshua H.
Director
Jun 4, 2026
AWARD90,000 sh
Jun 4, 2026
REICIN ALISE
Director
Jun 4, 2026
AWARD90,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
40,600,271
shares short
-0.6%
vs prior settlement
15.8
days to cover
≈13.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 5, 2026 SEC
Sana Biotechnology reported Q3 2026 GAAP net income of $20.4 million ($0.07 per share), driven by a $63.4 million…
8-K · Impact 4/10
Nov 5, 2026 SEC
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 37,293,854 shares of Sana…
SC 13G/A · Impact 2/10
Nov 5, 2026 Earnings result
SANA Q3 2026 Earnings: EPS $-0.14 (+7.4% vs est)
Oct 5, 2026 Insider
Bishop Hans Edgar was granted 8,680 shares
Director
Sep 30, 2026 Inst.
MORGAN STANLEY · DOUBLED
3,022,371 shares ($8.8M)
Sep 30, 2026 Inst.
Quadrature Capital Ltd · DOUBLED
303,761 shares ($885.5K)
Aug 27, 2026 Insider
PATEL DHAVALKUMAR DHIRAJLAL surrendered for taxes 41,158 shares
EVP, Chief Scientific Officer @ $4.11 ($169.2K)
Aug 26, 2026 Insider
PATEL DHAVALKUMAR DHIRAJLAL acquired via exercise 125,000 shares
EVP, Chief Scientific Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

9 filings · 3 press releases · 1 bullish · 1 bearish · 7 neutral
All SANA filing & press-release reports (12)